# TB-500 Legal

> A customs-form reading of the TB-500 regulatory record — every clearance stamp, every refused entry.

## Pages

- [TB-500 Legal — The regulatory record on Ac-LKKTETQ-OH, read like a passport](/index.md): A customs-form reading of the regulatory record on TB-500: FDA 503A Category 2, WADA S2 and S0, IFHA Article 6, USADA enforcement. Mechanism, evidence, and jurisdictional status of the seven-amino-acid fragment of Thymosin Beta-4.
- [TB-500 reported effects and safety — what the record shows](/effects.md): TB-500 reported effects, community signals, and safety cautions: what research-use communities describe, what animal studies show, and what the honest risk record looks like for the synthetic Thymosin Beta-4 fragment.
- [TB-500 Research Record — Mechanism, evidence, and clinical-program status](/research.md): The peer-reviewed research record on Thymosin Beta-4 and its synthetic fragment TB-500: G-actin sequestration, HIF-1α/VEGF angiogenesis, PINCH-ILK-Akt cardiac signaling, corneal repair, neurorestoration, and the active clinical-development landscape.
- [TB-500 Dosage in the Research Literature — Study-attributed ranges only](/dosage.md): The dose ranges and routes that appear in the peer-reviewed research literature on Thymosin Beta-4 and TB-500. Study-attributed values from rodent, porcine, equine, and human clinical work — not recommendations.
- [TB-500 Legal FAQ — Customs, controls, and the questions readers arrive with](/faq.md): Plain answers to the questions readers actually ask about TB-500's legal status: FDA Category 2, WADA, USADA, NCAA, customs, controlled substance status, research-only labeling, and the difference between TB-500 and Thymosin Beta-4.
- [TB-500 References — Customs manifest of the cited research and regulatory record](/references.md): Full citation list for the TB-500 Legal research record: 24 entries spanning Thymosin Beta-4 mechanism, preclinical studies, clinical trials, and regulatory actions, with DOIs and primary-source URLs.
- [About TB-500 Legal — Independent editorial publisher of regulatory and research summaries](/about.md): TB-500 Legal is an independent editorial project that publishes summaries of the peer-reviewed research and regulatory record on Thymosin Beta-4 and its synthetic fragment Ac-LKKTETQ-OH. Not a clinic, not a vendor.
- [Contact TB-500 Legal — Editorial correspondence channels](/contact.md): Editorial correspondence for TB-500 Legal: corrections, source suggestions, regulatory updates, and citation queries. The site does not provide medical, legal, or commercial services.